Skip to main content
. 2026 Feb 27;18(5):770. doi: 10.3390/cancers18050770
AML Acute Myeloid Leukemia
CR Complete Response
CRc Composite Complete Response
DLT Dose-Limiting Toxicity
EFS Event Free Survival
HSCT Hematopoietic Stem Cell Transplant
OS Overall Survival
RFS Relapse Free Survival